Important progress in product development – simultaneous staining in the same section, with high degree of detail
Lumito is developing a novel method for high-contrast imaging without background signal. The first application is developed for tissue diagnostics and digital pathology. In order to visualize cells containing Her2, which is a common marker in breast cancer diagnostics, Lumito is now presenting new images of breast tissues stained with the Company's Her2-UCNP reagent. Lumito's […]
The alpha prototype of the instrument delivered to Lumito according to plan
Lumito’s development partner TTP has delivered the alpha prototype of what will be Lumito’s first product. After delivery, the instrument has successfully undergone internal acceptance testing. The ongoing development phase of Lumito’s first product includes the development of an alpha prototype, with essential functionality implemented (“work like”), and thereafter a beta prototype, with complete implementation […]
Annual General Meeting of Lumito AB (publ) 2019
The annual general meeting of Lumito AB (publ), held in Lund on 4 June 2019, passed the following resolutions. Resolution on approval of the income statement and balance sheet, etc. The annual general meeting resolved to approve the income statement and balance sheet for the financial year 2018. The Board of Directors and the Managing […]
Lumito holds presentation on the Nordic Symposium on Digital Pathology
On 16 May, Lumito will demonstrate its technology under the theme "Open Innovation" on the Nordic Symposium on Digital Pathology in Linköping, with 200 expected participants from more than 10 countries. – This is an excellent opportunity to give a comprehensive presentation of our technology, and to meet pathologists and other representatives in the field […]
Communiqué from the extraordinary general meeting of Lumito AB (publ)
The extraordinary general meeting of Lumito AB (publ) on 25 April 2019 passed the following resolutions: Item 7 – Decision regarding the approval of the Board of Directors's proposal to issue new shares and warrants (units) Lumito’s Board of Directors has, conditional on the approval of the General Meeting, resolved to conduct a new issue […]
The Board of Lumito AB has decided to move the Annual General Meeting to 4 June
The Board of Lumito has decided to move the annual general meeting from 22 May to 4 June. The reason for the postponement is that the annual general meeting otherwise would have taken place in the middle of the subscription period for the new rights issue, as suggested by the Board. A notice convening the […]
Convocation of Extraordinary General Meeting of shareholders of Lumito AB (publ)
Shareholders of Lumito AB (publ), 556832-0062, are hereby convened to an Extraordinary General Meeting on Thursday, 25 April 2019, at 10:00 a.m. at Magistratsvägen 10, 226 43 Lund, Sweden. A. Right to participate at the Extraordinary General Meeting Shareholders who wish to participate at the extraordinary general meeting must be registered in the share […]
Convocation of Annual General Meeting of Lumito AB (publ)
Shareholders of Lumito AB (publ), Reg.no 556832-0062, are hereby convened to the Annual General Meeting on 4 June 2019, at 10:00 a.m., which will be held at the Company's premises at Gasverksgatan 1, 222 29 Lund, Sweden. Notification of participation Shareholders who wish to participate at the annual general meeting must: – be […]
Lumito – the first results from the new instrument prototype – significantly improved image quality.
Based on the results obtained from the concept phase, the new instrument prototype has been developed. Comparison made using the same microscope slides as the ones used in the concept phase with Lumito’s staining reagent shows significantly improved image quality. After the concept phase was completed during Q4 2018, phase two of the instrument and […]
Lumito presents results from the successful proof of concept phase
As previously disclosed the results from the first histological assay (Link to supporting material) (https://www.lumito.se/en/technology/concept-phase/) are very promising and corroborate a rapid development and release of Lumito’s unique products to the market. Lumito performed the assay together with the company’s development partner The Technology Partnership (TTP) and the external research laboratory BioIVT using proof of concept prototypes; tissue staining kit and instrument for […]